Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-CTLA4 monoclonal antibody GIGA-564

A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4; CTLA4; CD152), with potential immunomodulatory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody GIGA-564 targets and binds to CTLA-4, and may induce Fc receptor (FcR) signaling. This may deplete regulatory T cells (Tregs) in the tumor microenvironment (TME), decrease the proliferation of the remaining Tregs in the TME, and reactivate antitumor immune responses. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system. GIGA-564 has limited checkpoint inhibitory activity as it only weakly blocks the interaction between CTLA-4 and its B7 ligands CD80 and CD86.
Code name:GIGA 564
GIGA-564
GIGA564
Search NCI's Drug Dictionary